ArticleRevista da Associacao Medica Brasileira (1992)2025
When and why do children develop hyperglycemia during acute lymphoblastic leukemia therapy?
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors for hyperglycemia and evaluate the impact on outcomes among pediatric patients with acute lymphoblastic leukemia undergoing chemotherapy.
methodsWe conducted a retrospective cohort study involving 188 pediatric patients treated for acute lymphoblastic leukemia at a Brazilian cancer referral center between 2004 and 2017. Hyperglycemia was assessed during the induction and consolidation phases of chemotherapy. Associations with patient and disease characteristics were examined through multivariate analysis. Outcomes analyzed included severe infections, relapse, and mortality.
resultsHyperglycemia occurred in 43.6% of patients, predominantly during the induction phase. Pubertal status at diagnosis, younger age, and high relapse risk classification were independently associated with increased hyperglycemia risk. Puberty conferred a nearly 8-fold increased risk. However, hyperglycemia was not associated with increased risk of infections, relapse, or mortality. Higher mortality was observed among patients with overweight/obesity and those with pancreatitis or recurrent infections.
conclusionHyperglycemia was a frequent early adverse event in pediatric acute lymphoblastic leukemia treatment, particularly among pubertal patients and those at high relapse risk. Despite its high incidence, hyperglycemia was not associated with worse clinical outcomes in this cohort. These findings underscore the importance of early identification and monitoring, particularly during high-risk treatment phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.